Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target
Tóm tắt
Từ khóa
Tài liệu tham khảo
Carrascosa JM, 1984, Nitrogen movement between host and tumor in mice inoculated with Ehrlich ascitic tumor cells, Cancer Res, 44, 3831
Quesada AR, 1988, Contribution by host tissues to circulating glutamine in mice inoculated with Ehrlich ascites tumor cells, Cancer Res, 48, 1551
Elia I, 2016, Organ‐specific cancer metabolism and its potential for therapy, Handb Exp Pharmacol, 321
Bloch‐Frankenthal L, 1965, Fatty acid oxidation and ketogenesis in transplantable liver tumors, Cancer Res, 25, 732
Fields ALA, 1981, Regulation of energy metabolism in Morris hepatoma 7777 and 7800, Cancer Res, 41, 2762
Rashid A, 1997, Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia, Am J Pathol, 150, 201
Karpel‐Massler G, 2017, Metabolic reprogramming of glioblastoma cells by L‐asparaginase sensitizes for apoptosis in vitro and in vivo, Oncotarget, 7, 33512, 10.18632/oncotarget.9257
Hée VF, 2015, Lactate does not activate NF‐κB in oxidative tumor cells, Front Pharmacol, 6, 228
Quatromoni JG, 2012, Tumor‐associated macrophages: Function, phenotype, and link to prognosis in human lung cancer, Am J Transl Res, 4, 376
Ocaña MC, 2017, Metabolism in the tumor microenvironment: What is known about stromal and immune cells, Clin Immunol Endocr Metab Drugs, 33
Daurkin I, 2011, Tumor‐associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15‐lipoxygenase‐2 pathway, Microenviron Immunol, 71, 6400
Mitra R, 1977, Inhibition of mast cell population by L‐glutamine in aspirin‐induced ulceration in rat stomach, Indian J Physiol Pharmacol, 21, 374
Thomas L, 1982, On immunosurveillance in human cancer, Yale J Biol Med, 55, 329
Leek RD, 1996, Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma, Cancer Res, 56, 4625
Klimp AH, 2001, Expression of cyclooxygenase‐2 and inducible nitric oxide synthase in human ovarian tumors and tumor‐associated macrophages, Cancer Res, 61, 7305
Shapot VS, 1980, Biochemical Aspects of Tumour Growth
Mider GB, 1951, Some aspects of nitrogen and energy metabolism in cancerous subjects: A review, Cancer Res, 11, 821
Wu C, 1970, Responsiveness of glutamine‐metabolizing enzymes in Morris hepatomas to metabolic modulations, Cancer Res, 30, 2675
Gershtein ES, 1978, Kinetics of (C14) thymidine metabolism in hepatomas and tissues from normal and tumor‐bearing animals, Biokhimiia, 43, 1303
LePage GA, 1952, Growth of carcinoma implants in fed and fasted rats, Cancer Res, 12, 153
Cahlin C, 2000, Experimental cancer cachexia: The role of host‐derived cytokines interleukin (IL)‐6, IL‐12, interferon‐γ, and tumor necrosis factor α evaluated in gene knockout, tumor‐bearing mice on C57 Bl background and eicosanoid‐dependent cachexia, Cancer Res, 60, 5488
Shapot VS, 1974, Blood glucose levels and gluconeogenesis in animals bearing transplantable tumors, Cancer Res, 34, 1827
Pushkina IP, 1976, Correlation of membrane‐bound and free ribosomes in normal rat liver, Zajdela hepatoma rat liver and ascite cells proper, Biokhimiia, 41, 1940
Baker N, 1978, Regulation of plasma‐free fatty acid mobilization by dietary glucose in Ehrlich ascites tumor‐bearing mice, Cancer Res, 38, 2372
Holm E, 1995, Substrate balances across colonic carcinomas in humans, Cancer Res, 55, 1373
Catane R, 1979, Azaserine, DON, and azotomycin: Three diazo analogs of L‐glutamine with clinical antitumor activity, Cancer Treat Rep, 63, 1033
Yuan L, 2016, Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer, Am J Transl Res, 8, 4265
Prager MD, 1971, Metabolism of asparagine, aspartate, glutamine, and glutamate in lymphoid tissue: Basis for immunosuppression by L‐asparaginase, J Immunol, 106, 975, 10.4049/jimmunol.106.4.975
Roy S, 2005, Effect of glutamine analogue‐acivicin on tumor induced angiogenesis in Ehrlich ascites carcinoma, Indian J Exp Bol, 43, 407
Takigawa M, 1990, Tumor angiogenesis and polyamines: α‐difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma‐induced angiogensis in ovo and the proliferation of vascular endothelial cells in vitro, Cancer Res, 50, 4131
Skelton MS, 1995, Lactate influx into red blood cells of athletic and nonathletic species, Am J Physiol, 268, R1121
Liu Y, 2012, A small‐molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell‐cycle arrest, and inhibits cancer cell growth in vitro and in vivo, Ther Discov, 11, 1672
Floridi A, 1981, Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells, Cancer Res, 41, 4661
Elwood JC, 1968, Effect of oxamate on glycolysis and respiration in sarcoma 37 ascites cells, Cancer Res, 28, 2056
Baltazar F, 2014, Monocarboxylate transporters as targets and mediators in cancer therapy response, Histol Histopathol, 29, 1511
Sonveaux P, 2008, Targeting lactate‐fueled respiration selectively kills hypoxic tumor cells in mice, J Clin Invest, 118, 3930
Britten CD, 2000, A phase I and pharmacokinetic study of the mitochondrial‐specific rhodacyanine dye analog MKT 077, Clin Cancer Res, 6, 42
Zhang J, 2016, Glutamate dehydrogenase (GDH) regulates bioenergetics and redox homeostasis in human glioma, Oncotarget
Roberts LN, 1972, Clinical trial of a new antianginal drug: Perhexiline maleate, J Clin Pharmacol, 12, 342
Pizer ES, 1998, Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines, Cancer Res, 58, 4611
Zhou W, 2003, Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells, Cancer Res, 63, 7330
Boros LG, 1997, Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation, Cancer Res, 57, 4242
Siu LL, 2002, A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily‐times‐five every‐three‐week schedule in patients with advanced solid malignancies, Clin Cancer Res, 8, 2157